| Drugs |
Dose |
Duration of medication |
Anti-angiogenic drugs
| Vascular endothelial inhibitory protein |
7.5 mg/m2 |
Days 1-14, 1 cycle of 21 days |
| Bevacizumab |
7.5 to 15 mg/kg |
Day 1, 1 cycle of 21 days |
| Immunotherapy drugs |
| Sindilizumab |
200mg |
Day 1, 1 cycle of 21 days |
| Tirelizumab |
200mg |
Day 1, 1 cycle of 21 days |
| Carrilizumab (PD-1) |
200 mg |
Day 1, 1 cycle of 21 days |
| Navulizumab (PD-1) |
3mg/kg |
Day 1, 14-day cycle |
| Pabrolizumab (PD-1) |
200 mg |
Day 1, 21-day cycle |
| Atelelizumab (PD-L1) |
1200mg |
Day 1, 21-day cycle |
| Duvalizumab (PD-L1) |
10mg/kg |
Day 1, 14-day cycle |
| Targeted therapeutics |
| Gefitinib |
250mg |
1 dose/day |
Erlotinib
| 150mg |
1 dose/day |
Ecetinib
| 125mg |
3 doses/day |
Daclotinib
| 45mg |
1 dose/day |
Afatinib
| 40mg |
1 dose/day |
Oxitinib
| 80mg |
1 dose/day |
Crizotinib
| 250mg |
2 doses/day |
Aletinib
| 600mg |
2 doses/day |
Ceretinib
| 450mg |
1 dose/day |